Triple-negative breast cancer (TNBC) is an important subtype of breast cancer defined by the loss of estrogen receptor, progesterone receptor and human epidermal growth factor receptor type 2 (HER2), all of which are clinically important therapeutic targets because the major therapeutic strategies in breast cancer are hormone therapy and/or HER2 antibodies [3]. The gene discussed is ERBB2; the disease is breast carcinoma.